The most common side effects include abnormal liver tests, nausea, vomiting, difficulty breathing, abdominal pain, diarrhea, injection site reactions, headache, low blood potassium and skin rash.[10]
Isavuconazonium is used to treat invasive
aspergillosis and invasive
mucormycosis in adults aged eighteen years old and older. It is available in a capsule for administration by mouth and as a powder for administration via infusion.[9][7][8][12][14]
Contraindications
Isavuconazonium is contraindicated in people taking strong
CYP3A4 inhibitors, strong
CYP3A4 inducers, or moderate CYP3A4 or
CYP3A5 inducers.[7][8][9] It is contraindicated in people with familial short QT syndrome.[7][8][9]
Side effects
Common adverse effects (occurring in between 1 and 10% of people) include
low potassium, decreased appetite, delirium, headache, sleepiness,
vein inflammation, difficulty breathing, acute respiratory failure, vomiting, diarrhea, nausea, stomach pain, elevated results in
liver function tests, rash, itchy skin, kidney failure, chest pain, and fatigue. There are several uncommon side effects as well.[7][8]
In preclinical studies, isavuconazonium caused birth defects in animals; it has not been tested in pregnant women.[7][8][9]
Interactions
Isavuconazonium is converted into isavuconazole inside the body, and isavuconazole is a substrate for
CYP3A4 or
CYP3A5. Many other medications inhibit or induce those two enzymes, and isavuconazonium should not be administered with them. Inducers result in levels of isavuconazole that are too low and won't work, and inhibitors can cause high levels of isavuconazole which will in turn cause increased adverse events and toxicity. Likewise isavuconazonium can interfere with appropriate dosing of other drugs that are substrates for those enzymes.[7][8]
In addition, isavuconazole induces
CYP2B6 and can decrease the amount of drugs that are metabolized by the enzyme. Isavuconazole inhibits
P-glycoprotein (P-gp),
BCRP,
SLC22A2, and
uridine diphosphate-glucuronosyltransferases, each of which remove drugs from circulation; isavuconazonium will increase the amount of drugs that are affected by those proteins and may increase their toxicities.[7][8]
Pharmacology
After oral or intravenous administration, isavuconazonium is rapidly hydrolysed by
esterases in blood or the
gastrointestinal tract to the active form, isavuconazole.[7][8][15]
Isavuconazonium comprises an N-(3-acetoxypropyl)-N-methylamino-carboxymethyl group linked through an ester moiety to the triazole nitrogen in isavuconazole.[16][17][18]
In the aquatic media of the body, the isavuconazole molecule is transformed into monohydrate.[11]
History
Isavuconazole and isavuconazonium were discovered in Japan by researchers at
Roche's research center in
Kamakura.[16][19]Basilea Pharmaceutica, which had been spun out of Roche to develop antimicrobial assets, developed isavuconazonium through Phase II clinical trials. In February 2010, Basilea partnered with
Astellas Pharma to complete Phase III trials, obtain regulatory approvals, and market the drug. In 2013 and 2014, the partners won
orphan drug designation in the US for isavuconazonium for treating invasive aspergillosis, mucormycosis, and invasive candidiasis.[15][20][21][22]
In 2014, Basilea and Astellas amended the agreement to give Astellas sole marketing authority in North America, and Basilea the rights to market in the rest of the world.[23]
^
abc"Cresemba EPAR". European Medicines Agency (EMA). 17 September 2018.
Archived from the original on 10 August 2020. Retrieved 26 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^
abcVoronin AP, Vasilev NA, Surov AO, Churakov AV, Perlovich GL (2021). "Exploring the solid form landscape of the antifungal drug isavuconazole: crystal structure analysis, phase transformation behavior and dissolution performance". CrystEngComm. 23 (48): 8513–8526.
doi:
10.1039/D1CE01353J.
S2CID244426797.
^
abGuinea J, Bouza E (December 2008). "Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections". Future Microbiology. 3 (6): 603–15.
doi:
10.2217/17460913.3.6.603.
PMID19072177.
^"Proposed INN: List 96"(PDF). WHO Drug Information. 20 (4). 2006.
Archived(PDF) from the original on 5 September 2021. Retrieved 5 October 2020.
^"Recommended INN: List 58"(PDF). WHO Drug Information. 21 (3). 2007.
Archived(PDF) from the original on 17 September 2020. Retrieved 5 October 2020.
^Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, et al. (January 2003). "Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole". Bioorganic & Medicinal Chemistry Letters. 13 (2): 191–6.
doi:
10.1016/s0960-894x(02)00892-2.
PMID12482421.{{
cite journal}}: CS1 maint: overridden setting (
link)
^[hhttps://www.genengnews.com/topics/drug-discovery/astellas-takes-over-isavuconazole-manufacturing-and-promotion-in-u-s-canada/ "Astellas Takes Over Isavuconazole Manufacturing and Promotion in U.S., Canada"]. Genetic Engineering & Biotechnology News. 28 February 2014.
Archived from the original on 5 June 2023. Retrieved 21 May 2024.